





| 카탈로그 번호 | HX959076 |
|---|---|
| 설명 |
Ispectamab (HX959076) is a research-grade recombinant antibody targeting CD269. Produced in mammalian cells with native-like glycosylation.
Highlights
|
| 종 반응성 | Human |
| 응용 분야 | ELISA, Bioactivity: FCM, Functional assay, Research in vivo |
| 숙주 종 | Human |
| 클론성 | Monoclonal |
| 이소타입 | IgG1-kappa |
| 테스트된 응용 분야 | WB |
| 타겟 | B-cell maturation protein, BCM, BCMA, CD269, TNFRSF17, Tumor necrosis factor receptor superfamily member 17 |
| 내독소 수준 | < 10 EU/mg |
| 순도 | >95% as determined by SDS-PAGE. |
| 정제 | Protein A/G purified from cell culture supernatant. |
| 등록번호 | Q02223 |
| 형태 | Liquid |
| 저장 완충액 | 0.01M PBS pH 7.4. 데이터시트 인쇄본 또는 로트별 COA에 기재된 구체적인 완충액 정보를 참조하세요. |
| 안정성 및 저장 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 대체 이름 | BMS-986352, CC-99712, CC99712, CC99712, SP8919, 2413386-21-5 |
| 배경 | Tumor necrosis factor receptor superfamily member 17 (CD269/BCMA) is a ~20 kDa protein. Receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. Promotes B-cell survival and plays a role in the regulation of humoral immunity. Activates NF-kappa-B and JNK. CD269 is the therapeutic target of teclistamab (Tecvayli). |
| 참고사항 | For research use only. Not suitable for clinical or therapeutic use. |

Western blot analysis was performed using anti-CD269 monoclonal antibody at 1ug/mL on various samples.
Lane 1: recombinant human CD269 (Catalog No: HX959012)
Lane 2: negative control

SDS-PAGE for Research Grade Ispectamab.

Detects recombinant human CD269/TNFRSF17/BCMA (Catalog No: HX959012) in indirect ELISA






+86-027-65523339
중국 우한시 심둔사로 666번지 C동, 우한, 430206

中文
English
한국어
日本語
Español
Français
Русский